California Proposition 38 would authorize $8.4 billion in general obligation bonds to fund immunology and immunotherapy research, with half directed to a designated University of California-affiliated institute selected by the Department of Public Health and the remainder allocated via grants to public and nonprofit institutions, at least half of which must target cancer, heart disease, and Alzheimer’s. The measure caps administrative costs at 2 percent, requires royalty returns to the General Fund, and mandates discounted pricing for resulting therapies in California. Trader sentiment favoring rejection at 57.5 percent reflects primary concerns over the $500–600 million annual General Fund repayment obligation for roughly 20–25 years, skepticism about the earmarked institute structure versus competitive grant processes, and broader voter caution toward new debt amid competing fiscal measures on the November 2026 ballot. Opposition arguments in the voter guide highlight limited flexibility and uncertain revenue offsets from research commercialization.